Biohaven Net Working Capital from 2010 to 2024

BHVN Stock  USD 46.38  0.90  1.90%   
Biohaven Pharmaceutical Net Working Capital yearly trend continues to be very stable with very little volatility. Net Working Capital is likely to drop to about 274.1 M. During the period from 2010 to 2024, Biohaven Pharmaceutical Net Working Capital quarterly data regression pattern had sample variance of 20077 T and median of  59,879,000. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
387 M
Current Value
274.1 M
Quarterly Volatility
141.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Biohaven Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biohaven Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.3 M, Interest Expense of 1.2 M or Selling General Administrative of 60.1 M, as well as many indicators such as Price To Sales Ratio of 0.46, Dividend Yield of 0.0 or PTB Ratio of 7.48. Biohaven financial statements analysis is a perfect complement when working with Biohaven Pharmaceutical Valuation or Volatility modules.
  
Check out the analysis of Biohaven Pharmaceutical Correlation against competitors.

Latest Biohaven Pharmaceutical's Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Biohaven Pharmaceutical Holding over the last few years. It is Biohaven Pharmaceutical's Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biohaven Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Biohaven Net Working Capital Regression Statistics

Arithmetic Mean124,641,978
Geometric Mean85,708,221
Coefficient Of Variation113.68
Mean Deviation104,552,899
Median59,879,000
Standard Deviation141,693,492
Sample Variance20077T
Range444.1M
R-Value0.63
Mean Square Error12945T
R-Squared0.40
Significance0.01
Slope20,070,735
Total Sum of Squares281078.6T

Biohaven Net Working Capital History

2024274.1 M
2023387 M
2022496.9 M
202152.9 M

About Biohaven Pharmaceutical Financial Statements

Biohaven Pharmaceutical investors utilize fundamental indicators, such as Net Working Capital, to predict how Biohaven Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Working Capital387 M274.1 M

Pair Trading with Biohaven Pharmaceutical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biohaven Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biohaven Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Moving together with Biohaven Stock

  0.81OPT OptheaPairCorr

Moving against Biohaven Stock

  0.86FDMT 4D Molecular TherapeuticsPairCorr
  0.69RGNX RegenxbioPairCorr
  0.67NKTX Nkarta Inc Buyout TrendPairCorr
  0.65INKT Mink TherapeuticsPairCorr
  0.56MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
The ability to find closely correlated positions to Biohaven Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biohaven Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biohaven Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biohaven Pharmaceutical Holding to buy it.
The correlation of Biohaven Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biohaven Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biohaven Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biohaven Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Biohaven Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biohaven Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biohaven Pharmaceutical Holding Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biohaven Pharmaceutical Holding Stock:
Check out the analysis of Biohaven Pharmaceutical Correlation against competitors.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(9.37)
Return On Assets
(1.19)
Return On Equity
(2.65)
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.